Minerva plunges following delay in schizophrenia drug results

3 Likes

Damn another unsuccessful attempt…!!!

Chance of failing again…!!!

1 Like

No, it doesn’t have anything to do with the drug.

One of their vendors got hacked, causing delays.

It doesn’t have any impact on whether the drug will or will not meet its phase 3 goals.

Investors are upset because the company won’t have topline data by the end of the year and may have to secure more funding without that data, presumably at less favorable rates. They will still have the data by next year. This doesn’t affect the outcome, only the timeline.

2 Likes